VincentJPicozziMD

Oncology • Seattle, WA

Clinical Professor of Medicine, University Wash

Join to view full profile

Dr. Picozzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Picozzi's full profile

Already have an account?

Office
1100 9th Ave
Virginia Mason Med Ctr, Div Hem/Onc
Seattle, WA 98101
Phone+1 206-223-6600

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1981 - 1982
Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Stanford University School of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1981 - Present
WA State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 2
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT Start of enrollment: 2008 Sep 01
Completed
Phase 2
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
Completed
Phase 1, Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2014 Jul 31
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer Start of enrollment: 2018 Sep 17
Recruiting
Phase 1
Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology Start of enrollment: 2018 May 01
Recruiting
Phase 1
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Start of enrollment: 2019 May 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Treatment of advanced pancreatic cancer: When will the third time be a charm?
Vincent J Picozzi
Cancer. 2024-11-01
Pancreatic cancer: new approaches to drug therapy.
Vincent J Picozzi
International Journal of Surgery. 2024-10-01
Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Lyanne A Delgado-Coka, Lucia Roa-Peña, Sruthi Babu, Michael Horowitz, Emanuel F Petricoin 3rd
American Journal of Clinical Pathology. 2024-09-03

Journal Articles

Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative
Sameh Mikhail, Vincent J Picozzi, Clinical Cancer Research

Lectures

Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Pancreatic Cancer Survival Boosted by Novocure’s Wearable DeviceDecember 3rd, 2024
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerDecember 2nd, 2024
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerDecember 2nd, 2024
Join now to see all